Absci Stock Jumps

AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips
The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other industries.
AMD invests $20M in AI-powered drug discovery company Absci
Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop new hardware and software optimized for the healthcare sector. The effort will place particular emphasis on developing technologies that can advance drug discovery.
Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery
AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the company entered into a strategic collaboration with Advanced Micro Devices Inc (NASDAQ:AMD) to enhance its AI drug discovery capabilities.
AMD Invests in Absci to Strengthen AI Chip Presence in Drug Discovery
In a strategic move to expand its footprint in the healthcare sector, Advanced Micro Devices (AMD) has announced a $20 million investment in Absci, a Washington-based drug-discovery company. This investment not only highlights AMD’s ambition to diversify its market presence but also emphasizes the growing role of artificial intelligence (AI) in revolutionizing life sciences.
AMD invests $20 million in AI drug research at Vancouver-based Absci
Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial intelligence to develop new drug therapies. Absci hopes artificial intelligence will enable it to move faster to develop protein-based medicines called biologics,
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power critical AI drug discovery workloads,
AMD to invest $20m in Absci to boost AI drug discovery tech
AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design models.
Absci rises on $20M investment by Advanced Micro Devices
Absci (ABSI) was rising after a media report on a $20M investment by the semiconductor company Advanced Micro Devices (AMD) in the AI drug creation company.
Absci stock soars on AMD partnership and investment
Investing.com -- Shares of Absci Corporation (NASDAQ: ABSI) soared 50% following the announcement of a strategic collaboration and a $20 million investment from AMD (NASDAQ: AMD ). The partnership aims to enhance Absci's AI-driven drug discovery capabilities using AMD's Instinct accelerators and ROCm software.
Absci, Owkin announce partnership to bring together AI platforms
Absci (ABSI) and Owkin announced a partnership bringing together two leading AI platforms to rapidly discover and design ...
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Owkin, a TechBio that uses agentic AI to unlock complex targets for drug discovery, development, and diagnostics ...